PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study
Background Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prog...
Uložené v:
| Vydané v: | Radiation Oncology Ročník 17; číslo 1; s. 29 - 6 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
Springer Science and Business Media LLC
09.02.2022
BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1748-717X, 1748-717X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC.
Method and patients
A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side.
Results
Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89–1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56–1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41–0.94).
Conclusion
A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. |
|---|---|
| AbstractList | Background Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. Method and patients A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. Results Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89–1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56–1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41–0.94). Conclusion A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. Background Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. Method and patients A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. Results Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94). Conclusion A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. Keywords: Lung cancer, Non small cell lung cancer, PET/CT, Adaptive radiotherapy Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. Abstract Background Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. Method and patients A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. Results Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89–1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56–1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41–0.94). Conclusion A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94). A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. Background Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. Method and patients A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. Results Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89–1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56–1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41–0.94). Conclusion A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC.BACKGROUNDStage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC.A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side.METHOD AND PATIENTSA retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side.Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94).RESULTSPatients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94).A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning.CONCLUSIONA consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. |
| ArticleNumber | 29 |
| Audience | Academic |
| Author | Daniel Medenwald Lukas Käsmann Daniel F. Fleischmann Michael Oertel Danny Jazmati Matthias Mäurer Young DEGRO Trial Group |
| Author_xml | – sequence: 1 givenname: Matthias orcidid: 0000-0001-9662-3082 surname: Mäurer fullname: Mäurer, Matthias email: matthias.maeurer@med.uni-jena.de organization: Department of Radiation Oncology, University Medical Center Jena – sequence: 2 givenname: Lukas surname: Käsmann fullname: Käsmann, Lukas organization: Department of Radiation Oncology, University Hospital, LMU Munich – sequence: 3 givenname: Daniel F. surname: Fleischmann fullname: Fleischmann, Daniel F. organization: Department of Radiation Oncology, University Hospital, LMU Munich – sequence: 4 givenname: Michael surname: Oertel fullname: Oertel, Michael organization: Department of Radiation Oncology, University Medical Center Muenster – sequence: 5 givenname: Danny surname: Jazmati fullname: Jazmati, Danny organization: Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), University Hospital Essen – sequence: 6 givenname: Daniel surname: Medenwald fullname: Medenwald, Daniel organization: Department of Radiation Oncology, Faculty of Medicine, Martin Luther University Halle-Wittenberg |
| BackLink | https://cir.nii.ac.jp/crid/1873679868057341824$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/35139856$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1r3DAUNCWl-Wj_QA_F0Bx6caIP25IvhWW7TQOBlLKF3oQsybtabGkr2Qt760_vc5w02VCCsWRLM6M3T3OaHDnvTJK8x-gCY15eRkwRzjNESIZwVbGseJWcYJbzjGH26-jJ93FyGuMGobygqHqTHNMC04oX5Uny5_tieTlfZrWMRqdSy21vdyYNUlvfr02Q233qm7T1SrbtHgA76RQgoZQsdrCWKgNDO7hVqsatkFqXdkPbW2VcD7_7L4urH7fpDF6CMINSU-XXPvRp7Ae9f5u8bmQbzbv7-Sz5-XWxnH_Lbm6vruezm0wxRPpM01rmsmYNqRqNjOFMjuZVLgmhhGljyibXGDPG6roqiMYNUZqWSFWqLCilZ8n1pKu93IhtsJ0Me-GlFXcLPqyEDFB0a4SSHHPKkGY1zeFc2RhWVAWVqiZVSUatz5PWdqg7o0ejQbYHooc7zq7Fyu8E54ThahT4dC8Q_O_BxF50No6NlM74IQpSErg6hEsG0I_PoBs_BAetAhRFOYFbJY-olQQD1jUezlWjqJiVFS05RzwH1MV_UPBo01kF4WosrB8QPjw1-s_hQ34AwCeACj7GYBqhbC9760ffthUYiTGqYoqqgKiKu6iKAqjkGfVB_UUSnUgRwG5lwmM3XmSdTyxnLRQ4jpgzWrKKlxwVjOaYk5z-Bb4tAyM |
| CitedBy_id | crossref_primary_10_1053_j_semnuclmed_2022_04_001 crossref_primary_10_1007_s00066_025_02374_3 crossref_primary_10_1007_s00432_023_05289_7 crossref_primary_10_1007_s00066_025_02417_9 crossref_primary_10_1016_j_zemedi_2022_09_001 crossref_primary_10_1097_MNM_0000000000001898 |
| Cites_doi | 10.1007/s00066-021-01750-z 10.1016/j.ijrobp.2017.03.010 10.1016/S0025-6196(11)60735-0 10.1016/j.ijrobp.2005.06.034 10.1080/0284186X.2017.1409436 10.1186/s13014-018-1094-y 10.1200/JCO.19.01162 10.1159/000502202 10.3892/ol.2014.1874 10.1007/s00066-020-01727-4 10.1016/j.radonc.2014.10.001 10.1016/j.ijrobp.2013.05.003 10.1186/s13014-018-1147-2 10.1016/j.jval.2013.08.524 10.3109/0284186X.2015.1061209 10.1016/j.radonc.2017.02.011 10.1056/NEJMoa1709937 10.1016/j.lungcan.2011.07.018 10.1016/S1470-2045(20)30013-9 10.1016/S1470-2045(14)71207-0 10.6004/jnccn.2018.0062 10.1016/j.ijrobp.2017.10.042 10.3389/fonc.2020.564857 10.1016/j.radonc.2015.03.014 10.1183/16000617.0024-2019 10.1016/j.jtho.2018.09.021 10.1016/j.ijrobp.2017.06.250 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | Young DEGRO Trial Group |
| CorporateAuthor_xml | – name: Young DEGRO Trial Group |
| DBID | RYH C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QO 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH K9. M0S M1P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s13014-022-01997-5 |
| DatabaseName | CiNii Complete Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1748-717X |
| EndPage | 6 |
| ExternalDocumentID | oai_doaj_org_article_ca818370d7b343baafe75953acb29623 PMC8827193 A693688084 35139856 10_1186_s13014_022_01997_5 |
| Genre | Multicenter Study Journal Article Observational Study Report |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GrantInformation_xml | – fundername: Deutsche Forschungsgemeinschaft grantid: WI 830/12-1 funderid: http://dx.doi.org/10.13039/501100001659 – fundername: Friedrich-Schiller-Universität Jena (1010) – fundername: Deutsche Forschungsgemeinschaft grantid: WI 830/12-1 – fundername: ; – fundername: ; grantid: WI 830/12-1 |
| GroupedDBID | --- 0R~ 123 29P 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ ADUKV AENEX AFFHD AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ HMCUK HYE I-F IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV RYH SMD SOJ TUS UKHRP WOQ WOW ~8M PUEGO AAYXX CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7QO 7XB 8FD 8FK AZQEC DWQXO FR3 K9. P64 PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c702t-d3ba4ab7f29fd0ee87a3014c4a22327dee6f4d11777bb952d1f2cd360c9c65333 |
| IEDL.DBID | PIMPY |
| ISICitedReferencesCount | 7 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000753395200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1748-717X |
| IngestDate | Fri Oct 03 12:52:47 EDT 2025 Tue Nov 04 02:04:27 EST 2025 Fri Sep 05 06:59:47 EDT 2025 Tue Oct 21 12:46:21 EDT 2025 Tue Nov 11 10:10:41 EST 2025 Tue Nov 04 17:54:59 EST 2025 Thu Jan 02 22:55:13 EST 2025 Sat Nov 29 05:45:18 EST 2025 Tue Nov 18 20:55:43 EST 2025 Sat Sep 06 07:29:34 EDT 2025 Mon Nov 10 09:09:21 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Non small cell lung cancer Lung cancer PET/CT Adaptive radiotherapy |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c702t-d3ba4ab7f29fd0ee87a3014c4a22327dee6f4d11777bb952d1f2cd360c9c65333 |
| Notes | SourceType-Scholarly Journals-1 content type line 14 ObjectType-Report-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-6260-5249 0000-0001-9662-3082 0000-0002-2786-7013 |
| OpenAccessLink | https://www.proquest.com/publiccontent/docview/2630420042?pq-origsite=%requestingapplication% |
| PMID | 35139856 |
| PQID | 2630420042 |
| PQPubID | 55355 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ca818370d7b343baafe75953acb29623 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8827193 proquest_miscellaneous_2627480167 proquest_journals_2630420042 gale_infotracmisc_A693688084 gale_infotracacademiconefile_A693688084 pubmed_primary_35139856 crossref_citationtrail_10_1186_s13014_022_01997_5 crossref_primary_10_1186_s13014_022_01997_5 springer_journals_10_1186_s13014_022_01997_5 nii_cinii_1873679868057341824 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-09 |
| PublicationDateYYYYMMDD | 2022-02-09 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Radiation Oncology |
| PublicationTitleAbbrev | Radiat Oncol |
| PublicationTitleAlternate | Radiat Oncol |
| PublicationYear | 2022 |
| Publisher | Springer Science and Business Media LLC BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: Springer Science and Business Media LLC – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | JR Molina (1997_CR2) 2008; 83 U Nestle (1997_CR11) 2020; 21 C Ostheimer (1997_CR24) 2021; 197 JD Bradley (1997_CR5) 2017; 99 EHJ Tonk (1997_CR29) 2019; 12 Y Zheng (1997_CR8) 2014; 7 D De Ruysscher (1997_CR27) 2012; 75 P Hoegen (1997_CR23) 2020; 10 ML Bongers (1997_CR25) 2013; 16 FS Simsek (1997_CR12) 2020; 70 SE Schild (1997_CR13) 2019; 14 T Skripcak (1997_CR19) 2014; 113 RJHM Steenbakkers (1997_CR14) 2006; 64 RM Huber (1997_CR3) 2019; 28 S Thureau (1997_CR16) 2018; 13 N Jaksic (1997_CR6) 2018; 13 U Hoeller (1997_CR10) 2021; 118 JD Bradley (1997_CR18) 2015; 16 MD Jeter (1997_CR26) 2018; 100 W Wang (1997_CR22) 2013; 86 A Hallqvist (1997_CR15) 2017; 123 M Kandi (1997_CR20) 2018; 57 T Konert (1997_CR9) 2015; 116 DS Ettinger (1997_CR4) 2018; 16 JD Bradley (1997_CR17) 2020; 38 H Chen (1997_CR1) 2017; 98 SJ Antonia (1997_CR28) 2017; 377 P Berkovic (1997_CR21) 2015; 54 1997_CR7 |
| References_xml | – ident: 1997_CR7 doi: 10.1007/s00066-021-01750-z – volume: 70 start-page: 29 issue: 1 year: 2020 ident: 1997_CR12 publication-title: J Pak Med Assoc – volume: 98 start-page: 622 issue: 3 year: 2017 ident: 1997_CR1 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2017.03.010 – volume: 83 start-page: 584 issue: 5 year: 2008 ident: 1997_CR2 publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)60735-0 – volume: 64 start-page: 435 issue: 2 year: 2006 ident: 1997_CR14 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2005.06.034 – volume: 118 start-page: 205 issue: 12 year: 2021 ident: 1997_CR10 publication-title: Dtsch Arztebl Int – volume: 57 start-page: 813 issue: 6 year: 2018 ident: 1997_CR20 publication-title: Acta Oncol doi: 10.1080/0284186X.2017.1409436 – volume: 13 start-page: 147 issue: 1 year: 2018 ident: 1997_CR6 publication-title: Radiat Oncol (Lond Engl) doi: 10.1186/s13014-018-1094-y – volume: 38 start-page: 706 issue: 7 year: 2020 ident: 1997_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.19.01162 – volume: 12 start-page: 621 issue: 2 year: 2019 ident: 1997_CR29 publication-title: Case Rep Oncol doi: 10.1159/000502202 – volume: 7 start-page: 1015 issue: 4 year: 2014 ident: 1997_CR8 publication-title: Oncol Lett doi: 10.3892/ol.2014.1874 – volume: 197 start-page: 385 issue: 5 year: 2021 ident: 1997_CR24 publication-title: Strahlenther Onkol doi: 10.1007/s00066-020-01727-4 – volume: 113 start-page: 303 issue: 3 year: 2014 ident: 1997_CR19 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2014.10.001 – volume: 86 start-page: 956 issue: 5 year: 2013 ident: 1997_CR22 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2013.05.003 – volume: 13 start-page: 208 issue: 1 year: 2018 ident: 1997_CR16 publication-title: Radiat Oncol doi: 10.1186/s13014-018-1147-2 – volume: 16 start-page: A414 issue: 7 year: 2013 ident: 1997_CR25 publication-title: Value Health doi: 10.1016/j.jval.2013.08.524 – volume: 54 start-page: 1438 issue: 9 year: 2015 ident: 1997_CR21 publication-title: Acta Oncol doi: 10.3109/0284186X.2015.1061209 – volume: 123 start-page: 71 issue: 1 year: 2017 ident: 1997_CR15 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2017.02.011 – volume: 377 start-page: 1919 issue: 20 year: 2017 ident: 1997_CR28 publication-title: N Engl J Med doi: 10.1056/NEJMoa1709937 – volume: 75 start-page: 141 issue: 2 year: 2012 ident: 1997_CR27 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2011.07.018 – volume: 21 start-page: 581 issue: 4 year: 2020 ident: 1997_CR11 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30013-9 – volume: 16 start-page: 187 issue: 2 year: 2015 ident: 1997_CR18 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71207-0 – volume: 16 start-page: 807 issue: 7 year: 2018 ident: 1997_CR4 publication-title: J Natl Compr Cancer Netw doi: 10.6004/jnccn.2018.0062 – volume: 100 start-page: 730 issue: 3 year: 2018 ident: 1997_CR26 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2017.10.042 – volume: 10 start-page: 564857 year: 2020 ident: 1997_CR23 publication-title: Front Oncol doi: 10.3389/fonc.2020.564857 – volume: 116 start-page: 27 issue: 1 year: 2015 ident: 1997_CR9 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2015.03.014 – volume: 28 start-page: 190024 issue: 152 year: 2019 ident: 1997_CR3 publication-title: Eur Respir Rev doi: 10.1183/16000617.0024-2019 – volume: 14 start-page: 298 issue: 2 year: 2019 ident: 1997_CR13 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.09.021 – volume: 99 start-page: S105 issue: 2 year: 2017 ident: 1997_CR5 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2017.06.250 |
| SSID | ssj0045309 ssib019758958 ssib044219063 |
| Score | 2.3224738 |
| Snippet | Background
Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show... Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising... Background Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show... Abstract Background Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer nii |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 29 |
| SubjectTerms | Adaptive radiotherapy Adenocarcinoma Aged Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - radiotherapy Care and treatment Chemoradiotherapy Chemotherapy Clinical Radiation Oncology Cohort Studies Computed tomography CT imaging ddc:610 ddc:615 Development and progression Diagnosis Drug dosages Female Heterogeneity Humans Imaging Irradiation Lung cancer Lung cancer, Non-small cell Lung Neoplasms Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Male Medical physics. Medical radiology. Nuclear medicine Medical prognosis Medical research Medizin Methods Middle Aged Neoplasm Staging Neoplasms. Tumors. Oncology. Including cancer and carcinogens Non small cell lung cancer Non-small cell lung carcinoma Oncology Patients PET imaging PET/CT Planning Positron Emission Tomography Computed Tomography Prognosis R895-920 Radiation Radiation therapy Radiology Radiotherapy Radiotherapy, Image-Guided RC254-282 Registration Retrospective Studies Short Report Small cell lung carcinoma Strategy Survival Survival Rate Toxicity Tumors |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZghRAXxJssu8hISBwgauIkfhzL0oUDLCtU0N4sxw8RqaSrtrtSb_x0ZpykEJ4XpLZSYyeyZ8bzyIw_E_JUem8rV7s0L7hNS2V5akSI6yrkQTnJ4hlLn96KkxN5dqZOfzjqC2vCOnjgjnATa8CkFCJzoi7KojYmeFGpqjC2ZgpsN2rfTKghmOp0cFkVmRq2yEg-WecYOaRYuZ5F_NFqZIYiWv9OJ19tm-Z3_uavZZM_5U6jSTq-RW72viSddnO4Ta749g65_q7Plt8lX09n88nRPEVL5ahx5hx1G10Z1_T7rrZ0GWg0Z4stHcoBaLts0_UXuEbxtT5dgD6gFptWtGlpLEHEwcHf7avZ6w_v6RS-DA1RllM8cXe1oRG29h75eDybH71J-xMXUisytkkdELg0tQhMBZd5L4VBwtnSgBfBhPOeh9JhnlfUtaqYywOzruCZBSaD41jcJ3swRv-QUOBSqGtM3FUOnDSpAoSOTviKSW9NcAnJBwZo28OR46kYCx3DEsl1xzQNTNORabpKyPPdPecdGMdfe79Evu56IpB2vADipXvx0v8Sr4Q8Q6nQuNxheNb0uxZgkgicpadcFRx0oCwTcjDqCcvUjpoPQa5gqvibS1Fg-otLxKMsIcbD2weJ070aWWvG8W0TKtaEPNk145OxNK71ywvswwRiAHGRkAedgO6mXFTg4MuKJ0SMRHdEk3FL23yOIOMQeQlw7hPyYhDy78P6M833_wfNH5EbLC5V-KgDsrdZXfhDcs1ebpr16nFc6N8Ai3RQaw priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Journals dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw0GIDIV74HgQ2ZCQkHiBa4iS281hGBw8wplGmvVmOPyBSSaekQ-obP507NykKDCSQmkqNz5Hvcp-985mQZ9I5U9jKxmnGTZyXhsda-CBXPvWllSycsXT6ThwdybOz8rjfFNYN1e5DSjJo6iDWku93KXr_MVafJ6GHaLFFroK5E1jId_LxdNC_eZEl5bA95tJ5IxMUOvVv9PFWU9eX-Zq_l0z-kjcN5ujw1v8hcpvc7N1POlnzyx1yxTV3yfX3fYL9Hvl-PJ3tH8xiNG6WaqvPUR3SVtu636q1ogtPgwWcr-hQQUCbRRN3X-EexUwAnYMKoQaHWlo3NFQtIk7wc_V6-ubkA53AxdB2JSnFQ3rbJQ2dbu-TT4fT2cHbuD-kITYiYcvYZpXOdSU8K71NnJNCI3om1-B4MGGd4z63mBoWVVUWzKaeGZvxxABfgK-Z7ZBtWKN7SKgTha8qzPUVFvw6WXqINq1wBZPOaG8jkg7vTZm-gzkepDFXIZKRXK1Jq4C0KpBWFRF5sZlzvu7f8VfoV8gOG0jsvR1uLNrPqhdlZTQ4OZlIrKiyHLDXHhZeFpk2FSvBm4zIc2QmhRoClmd0v9EBkMReW2rCy4yD2pR5RHZHkCDZZjS8B-wIqOJ3KkWGGTMusYVlDmEhTh8YVfWap1OM4x9UqIsj8nQzjE_GarrGLS4QhglsG8RFRB6s-XqDclZATCALHhEx4vgRTcYjTf0l9CWHYE1APBCRlwPf_1zWn2n-6N_AH5MbLIgOfMpdsr1sL9weuWa-LeuufRI0wQ-guFSC priority: 102 providerName: Springer Nature |
| Title | PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study |
| URI | https://cir.nii.ac.jp/crid/1873679868057341824 https://link.springer.com/article/10.1186/s13014-022-01997-5 https://www.ncbi.nlm.nih.gov/pubmed/35139856 https://www.proquest.com/docview/2630420042 https://www.proquest.com/docview/2627480167 https://pubmed.ncbi.nlm.nih.gov/PMC8827193 https://doaj.org/article/ca818370d7b343baafe75953acb29623 |
| Volume | 17 |
| WOSCitedRecordID | wos000753395200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1748-717X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045309 issn: 1748-717X databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1748-717X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045309 issn: 1748-717X databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1748-717X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045309 issn: 1748-717X databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1748-717X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045309 issn: 1748-717X databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1748-717X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045309 issn: 1748-717X databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1748-717X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045309 issn: 1748-717X databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Journals customDbUrl: eissn: 1748-717X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045309 issn: 1748-717X databaseCode: RSV dateStart: 20061201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZoixAX3o_AbmUkJA4QNXEedk6ou3QBiS1VKavuKXJsByKVtKRdpN746cy4SVfhsSektlJip_Ik488zmfE3hDwXxqhIZ9r1g1i5YaJiV_LczqvczxMtmK2xdPaBj8diPk8m9fbodZ1W2WCiBeod2zPmbQMID_RS4RvzAYvRDUeNe7367mINKYy11gU1OqSHxFusS3qT96eT8waZwyjwkmbjjIgHax_9CRfz2T3LShq1FifL4b9H6k5ZFH-zQv9MpvwtomoXqpPb_1fEO-RWbbDS4U7D7pJrprxHbpzWIfn75OdkNBscz1xcDjWVWq4QQGkldVFv7trSZU7tmrnY0ibngJbL0l1_g3MUYwd0AaBDFTZVtCipzXNEWeFw-2b0dvqRDuHLcLXzfIplfasNtdy4D8jnk9Hs-J1bl3VwFffYxtVBJkOZ8ZwlufaMEVzic1ChBFOFcW1MnIcag8k8y5KIaT9nSgexp0CTwDoNHpIujNE8JtTwKM8yjA5GGixBkeTgn2puIiaMkrl2iN88z1TVnOdYemORWt9HxOlOB1LQgdTqQBo55OX-mtWO8ePK3keoJvueyNZtTyyrL2k9-VMlwSwKuKd5FoQgvcxh4EkUSJWxBOxPh7xAJUsRU2B4StZbI0BIZOdKh3ESxAC0InTIQasnYIFqNR-CmoKo-OsLHmCMLRZIehmCI4mXN5qX1li1Ti8VzSHP9s34z5h_V5rlBfZhHImGYu6QRzt934scROBFiCh2CG_NhNY9abeUxVfLZA7uHQcPwiGvmjlzOax_3_MnV0vxlNxkdk7DJzkg3U11YQ7JdfVjU6yrPunwObe_ok96R6PxZNq3L2L6NVrA0fTT2S-LnnCa |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF61BQEX3g9DC4sE4gBW7PVj7QNCoU1p1bRUKKDclvXuGiwFJzgpKDd-Eb-RmY3tyjx66wEpiRTv2trZfPPKzM4Q8iQxRkU6064fxMoNUxW7kueWr3I_T3XCbI-lD0N-dJSMx-nxGvnZnIXBtMpGJlpBracK_yPvsRgdb8TYq9lXF7tGYXS1aaGxgsWBWX4Hl23-cn8Hft-njO0ORtt7bt1VwFXcYwtXB5kMZcZzlubaMybhEt0KFUrQlIxrY-I81BjL5FmWRkz7OVM6iD0FhIBxFMBz18kFkOMcOybwcevghVHgpc3BnCTuzX18sIv58p6tehp1lJ_tEdBqgvWyKP5m5f6ZrPlbxNYqwt1r_9sWXidXa5Ob9lc8coOsmfImuXRYJxXcIj-OB6Pe9shFha6p1HKGKoBWUhf18bQlnebUav3JkjZZE7Sclu78C1yjGP2gExCbVOFQRYuS2kxN3E34utwZvHn3lvbhzVBfez7FxsTVgtrqvrfJ-3Oh_w7ZgDWae4QaHuVZhvHNSIMtm6Q5eNiam4glRslcO8RvECNUXbUdm4dMhPXeklisUCYAZcKiTEQOed7eM1vVLDlz9msEYjsT643bC9Pqk6jFl1ASDLuAe5pnQQjUyxwWnkaBVBlLwYJ2yDOEsUCpCMtTsj7cAURifTHRj9MgBlWRhA7Z7MwEaaY6w1vACEAqfvoJDzBKGCdYtjMEVxhvb7Atamk7F6fAdsjjdhifjBmEpZme4BzGsVRSzB1yd8VRLclBBH5QEsUO4R1e6-xJd6QsPtta7OCgcvCBHPKi4crTZf17z--fTcUjcnlvdDgUw_2jgwfkCrMSBF7pJtlYVCdmi1xU3xbFvHpo5Q8lH8-bW38BCBa7qQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbYQBMv3AeBDYyExANEzd3OY9laQIxSQZn2Zjm-QKSSVmmH1Dd-Ouc4SSEwkBBSU6mxHfk459pz_JmQJ9wYlepC-2GcKT_JVeZLZp1c2dDmmkfujKXTEzaZ8LOzfPrTLn5X7d6lJJs9DYjSVK0HS20bEefZYBViJOBjJXrg8ETTHXI5wXI5jNc_nHa6OEnjIO-2ylw4rmeOHGr_VjfvVGV5kd_5e_nkLzlUZ5rG1_-fqBvkWuuW0mHDRzfJJVPdIntv28T7bfJtOpoNjmY-Gj1NpZZLVJO0lrpst3Bt6MJSZxnnG9pVFtBqUfmrL3CPYoaAzkG1UIVNNS0r6qoZkT74uTkevXz_jg7hitCmBSHFw3vrNXUIuHfIx_FodvTKbw9v8BULorWv40ImsmA2yq0OjOFMInkqkeCQREwbk9lEY8qYFUWeRjq0kdJxFijgF_BB432yC3M09wg1LLVFgTnAVIO_x3MLUahmJo24UdJqj4TdOxSqRTbHAzbmwkU4PBPN0gpYWuGWVqQeebYds2xwPf7a-wWyxrYnYnK7G4v6k2hFXCgJzk_MAs2KOAHqpYWJ52ksVRHl4GV65CkylkDNAdNTst0AAUQiBpcYZnmcgTrliUcOej1B4lWv-RBYE0jF75CzGDNpGUdoywTCRRzeMa1oNdJKRBn-cYU62iOPt834ZKyyq8ziHPtEDOGEMuaRuw2Pb0mOU4gVeJp5hPW4v7cm_Zaq_OzwyiGIYxAneOR5JwM_pvXnNb__b90fkb3p8VicvJ68eUCuRk6K4JMfkN11fW4OyRX1dV2u6odOQXwHmFNgQQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PET%2FCT-based+adaptive+radiotherapy+of+locally+advanced+non-small+cell+lung+cancer+in+multicenter+yDEGRO+ARO+2017-01+cohort+study&rft.jtitle=Radiation+oncology+%28London%2C+England%29&rft.au=M%C3%A4urer%2C+Matthias&rft.au=K%C3%A4smann%2C+Lukas&rft.au=Fleischmann%2C+Daniel+F&rft.au=Oertel%2C+Michael&rft.date=2022-02-09&rft.pub=Springer+Nature+B.V&rft.eissn=1748-717X&rft.volume=17&rft.spage=1&rft_id=info:doi/10.1186%2Fs13014-022-01997-5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1748-717X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1748-717X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1748-717X&client=summon |